Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients
Open Access
- 1 July 2017
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 23 (7) , 1122-1127
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Pediatric Blood & Cancer, 2015
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosisFuture Oncology, 2015
- How we treat chronic graft-versus-host diseaseBlood, 2015
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseBlood, 2014
- The best endpoint for acute GVHD treatment trialsBlood, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Infliximab for GVHD therapy in childrenBone Marrow Transplantation, 2007
- How I treat refractory acute GVHDBlood, 2007
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974